UBS O'Connor’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

UBS O'Connor’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-499,982	Closed	-$4.96M	–	1012
2021 Q3	$4.96M	Hold	499,982	–	–	0.04%	242
2021 Q2	$4.97M	Hold	499,982	–	–	0.04%	207
2021 Q1	$4.98M	Sell	499,982 -115,954	-19%	-$1.24M	0.07%	208
2020 Q4	$6.65M	Sell	615,936 -296,561	-32%	-$3.05M	0.14%	161
2020 Q3	$9.45M	Sell	912,497 -465,003	-34%	-$4.83M	0.24%	63
2020 Q2	$13.8M	Buy	+1,377,500	New	+$13.7M	0.31%	80

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

UBS O'Connor's STLN Position: Q4 2021 in Review

UBS O'Connor sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 499,982 shares — an estimated $4.96M sold.

UBS O'Connor first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $13.8M in Q2 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

UBS O'Connor reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
UBS O'Connor sold 499,982 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $4.96M.
UBS O'Connor first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
UBS O'Connor's Starling Oncology Institute, Inc. Common Stock position peaked at $13.8M in Q2 2020.
21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.